Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients

Movement Disorders

Volumn 20, Issue 1, 2005, Pages 69-72

  Lamberti, Paolo ^a   Zoccolella, Stefano ^a   Iliceto, Giovanni ^a   Armenise, Elio ^a   Fraddosio, Angela ^a   de Mari, Michele ^a   Livrea, Paolo ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

COMT inhibitors; Homocysteine; Levodopa; Parkinson's disease

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; CYANOCOBALAMIN; ENTACAPONE; FOLIC ACID; HOMOCYSTEINE; LEVODOPA;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLIC ACID BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VITAMIN BLOOD LEVEL;

AGED; ANTIPARKINSON AGENTS; CASE-CONTROL STUDIES; CATECHOLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG THERAPY, COMBINATION; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; LEVODOPA; LINEAR MODELS; MALE; MIDDLE AGED; PARKINSON DISEASE; VITAMIN B 12;

EID: 14044279299     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20261     Document Type: Article

References (16)

1. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma Homocysteine as a risk factor for vascular disease. JAMA 1995;274:1049-1057.
2. Riggs KM, Spiro A, Tucker KL, Rush D. Relations of vitamin B12, vitamin B6, folate and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr 1996;63: 306-314.
3. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346:476-483.
4. Morris MS. Homocysteine and Alzheimer's disease. Lancet Neurol 2003;2:425-428.
5. Allain P, LeBouil A, Cordillet E, Le Quay L, Bagheri H, Montastruc JL. Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicology 1995;16:527-529.
6. Kuhn W, Roebroek R, Blom H, et al. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol 1998;40:225-227.
7. Muller T, Werne B, Fowler B, Kuhn W. Nigral endothelial dysfunction, homocysteine and Parkinson's disease. Lancet 1999;354: 126-127.
8. Daly D, Miller JW, Nadeau MR, Selhub J. The effect of L-dopa administration and folate deficiency on plasma homocysteine concentrations in rats. J Nutr Biochem 1997;8:634-640.
9. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa. Arch Neurol 2003;60:59-64.
10. Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA. Effects of L-dopa on plasma homocysteine in PD patients. Relationship to B-vitamin status. Neurology 2003;60:1125-1129.
11. Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 2000;55:437-440.
12. Yasui K, Nakaso K, Kowa H, Takeshima T, Nakashima K. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. Acta Neurol Scand 2003;108:66-67.
13. Miller JW, Shukitt-Hale B, Villabos-Molina R, Nadeau MR, Selhub J, Joseph JA. Effect of L-dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol 1997;20:55-66.
14. Nakaso K, Yasui K, Kowa H, et al. Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-dopa, homocysteine and MTHFR genotype. J Neurol Sci 2003;207:19-23.
15. Jellinger KA. Prevalence of stroke in Parkinson's disease. Mov Dis 2003;18:723-724.
16. Mastaglia FM, Johnsen RD, Kakulas BA. Prevalence of stroke in Parkinson's disease: a postmortem study. Mov Dis 2002;17:772-774.